Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected i
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesComparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesThe Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbsAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloBinding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategyDissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.Progress on new vaccine strategies against chronic viral infectionsRepeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensRemoval of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesCross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteersCharacterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.Genetic diversity of pneumococcal surface protein A in invasive pneumococcal isolates from Korean children, 1991-2016.
P2860
Q27489000-FC897268-A1C2-48F8-A3DA-650351A06716Q29619015-BF0E1F89-8532-435A-B02C-3FA9CBF79CC9Q30360326-BA14BAB2-3DE6-45D9-91A6-4FADDCD77FEFQ30524225-7616E93F-CF36-453F-AD8C-D95A4B23CCAAQ33835295-470F72F2-728C-47DC-91D9-A194B23DAC7BQ33842286-192125D8-86D4-49DD-8E75-D90B5C2D5BF3Q33843103-03F50571-2FED-4290-AD96-0BCC82CF24A3Q33850612-93579D45-4099-42E1-8D86-EF6B2DEE4031Q34154514-D84656E0-FBD5-4AA2-806F-B6A3C6B78FEAQ34303849-7ACF806A-BFDF-429C-9D46-EB78A4474521Q34539819-EA030406-4B01-4C31-B179-7341F9E903A2Q35024202-232AA360-F1AC-4B62-B697-18E221635F59Q35077716-354469A8-483F-4F7E-9D7C-7D5F93A549FCQ35140032-83454F02-1C79-45B2-9ED5-9B512D95A9CCQ35785338-CC2C1A62-70F8-4F0C-911C-BA98E7AE9AF9Q35857221-6500F0AF-2F79-424A-B1EA-0F1243FD9909Q35864857-17269C56-4089-44F0-8BCE-AC64E6D67684Q36051764-D3D7C291-175B-426E-8724-C845238076AEQ36099119-F66295D8-8795-49F8-B8FA-1FC08E181028Q36138144-5AA1DC3F-51C2-44B4-82CA-A1F8EDC526C8Q36424574-5307BB0F-C420-43DC-B469-B14361F6701CQ36528901-C4D7581F-4C95-490E-B8F1-1DD964806347Q37072702-4FB94DAA-EB48-405B-BD82-CA8B205520C2Q39699309-ECB1FFDE-A848-4866-BFAA-3B11A9AE797CQ42554027-EB3C51EA-D287-496E-AD6D-BE4E74C975CCQ45709889-BE79CD12-51F9-45B4-88CF-F83FD41AEB29
P2860
Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected i
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Comparison of the antibody rep ...... sera from naturally infected i
@en
Comparison of the antibody rep ...... sera from naturally infected i
@nl
type
label
Comparison of the antibody rep ...... sera from naturally infected i
@en
Comparison of the antibody rep ...... sera from naturally infected i
@nl
prefLabel
Comparison of the antibody rep ...... sera from naturally infected i
@en
Comparison of the antibody rep ...... sera from naturally infected i
@nl
P2093
P2860
P1433
P1476
Comparison of the antibody rep ...... naturally infected individuals
@en
P2093
P2860
P304
P407
P577
1999-02-01T00:00:00Z